Please provide your email address to receive an email when new articles are posted on . The highest percentages of patients with HBsAg loss were observed in the groups that received xalnesiran plus an ...

Hepatitis B virus (HBV) infects more than 250 million people worldwide and can lead to chronic liver disease and liver cancer. Current antiviral therapies suppress viral replication but do not ...

By broadening definition of success to include sustained low-level HBsAg with suppressed HBV DNA, we can recognize clinically ...

HBsAg, hepatitis B surface antigen; ALT, alanine aminotransferase; ULN, the upper limit of normal; TDF, tenofovir disoproxil fumarate; HBV, hepatitis B virus; anti-HBs, hepatitis B surface antibody.

Aligos Therapeutics has initiated dosing in the randomised Phase II B-SUPREME trial of its oral therapy, ALG-000184, in people with chronic hepatitis B virus (HBV) infection. The double-blind, ...

St. Louis -- In a pair of articles published in Lancet Gastroenterology and Hepatology, scientists lay out the case for why we should expand treatment recommendations for people with hepatitis B.

Please provide your email address to receive an email when new articles are posted on . PHILADELPHIA — Paul Kwo, MD, professor of medicine at Stanford University, speaks with Healio about ...

Among people with hepatitis B virus infection who met treatment criteria, only 57.2% received treatment, a cross-sectional study showed. For people with advanced fibrosis or diagnosed cirrhosis/liver ...